NCT00468806已完成1 期
An Open Label Positron Emission Tomography Study in Healthy Male Subjects to Investigate Brain Dopamine D3 Occupancy Kinetics, Pharmacokinetics and Safety of Single Oral Doses of GSK598809, Using [11C]-(+)-PHNO as PET Ligand.
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 25
- 试验地点
- 2
- 主要终点
- %D3 RO at Tmax
研究概览
简要总结
The purpose of this study is to look at how much of a new drug, GSK598809 binds to specific proteins in the brain and how much stays in the blood over a range of different doses.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 25 Years 至 55 Years（Adult）
- 性别
- Male
- 接受健康志愿者
- 是
入选标准
- •Healthy male subjects, defined as individuals who are free from clinically significant illness or disease as determined by their medical history (including family), physical examination, laboratory studies, and other tests.
- •Aged 25-55 years inclusive, at screening visit.
- •Body weight > 50 kg and body mass index (BMI) between 19.0 - 29.0 kg/m2 inclusive.
- •Capable of giving informed consent and can comply with the study requirements and timetable.
- •Self-administered Beck Depression Inventory II scale total score no greater than 9, and suicide question score of zero.
- •Able to read, comprehend and record information.
- •A signed and dated written informed consent is obtained from the subject.
排除标准
- •The physician responsible considers the subject unfit for the study based upon medical history, physical examination and psychiatric history and evaluation.
- •History of a drug or other allergy which in the opinion of the physician responsible contraindicates their participation in the study.
- •Participation in a clinical trial and has received a drug or a new chemical entity within 30 days or 5 half-lives, or twice the duration of the biological effect of any drug(whichever is longer) prior to the first dose of current study medication.
- •Exposure to more than four new chemical entities within 12 months prior to the first dosing day.
- •A screening ECG outside of ranges specified in the protocol
- •Pulse rate <55 or >100 bpm OR a systolic blood pressure >140 and <100 OR a diastolic blood pressure >90 and <
- •History of long QT syndrome (personal or family) or other cardiac conduction disorder, or other clinically significant cardiac disease.
- •An electrolyte value outside the normal range at pre-study screening. Subjects who do not fall within the normal reference ranges may be included within the study if in the opinion of the Principal Investigator and Medical Monitor this will not compromise the subject.
- •Liver function tests (LFT) elevated above the reference range at pre-study screening that remain elevated with a repeat LFT.
- •Any other clinically significant laboratory abnormality.
- •Use of prescription or non-prescription drugs, including vitamins, herbal and dietary supplements (including St John'sWort) within 7 days (or 14 days if the drug is a potential enzyme inducer) or 5 half-lives (whichever is longer) prior to the first dose of study medication, unless in the opinion of the Investigator and sponsor the medication will not interfere with the study procedures or compromise subject safety.
- •History of regular alcohol consumption averaging >14 drinks/week for men. One drink is equivalent to(12 g alcohol) = 5 ounces (150 ml) of wine or 12 ounces (360 ml) of beer or 1.5 ounces (45 ml) of 80 proof distilled spirits) within 6 months of screening.
- •Smokes or has smoked in the last 6 months.
- •Donation of more than 450 ml blood within the 56 days before dosing.
- •An unwillingness of male subjects to abstain from sexual intercourse with pregnant or lactating women from the time of administration of study medication (GSK598809) until 90 days following administration of study medication or an unwillingness of the male subject to use a condom/spermicide in addition to having their female partner use another form of contraception if the woman could become pregnant from the time of administration of study medication until 90 days following administration of study medication.
- •Current or recent (within one year) gastrointestinal disease; a history of malabsorption, esophageal reflux, irritable bowel syndrome; frequent (more than once a week) occurrence of heartburn; or any surgical intervention (e.g., cholecysectomy) which would be expected to influence the absorption of drugs.
- •Any previous or current psychiatric diagnosis listed in DSMIV Axis I or II.
- •Any history of suicidal attempts, suicidal ideation or behaviour.
- •Chronic Hepatitis B and C, as evidenced by positive Hepatitis B surface antigen (HBsAg) or Hepatitis C antibody.
- •A positive test for HIV.
- •Past history of drug abuse (i.e. meeting DSM IV or ICD 10 criteria for substance dependence) or has tested positive for urine drugs of abuse at pre-study screening and/or prior to dosing.
- •Previous inclusion in a research and/or medical protocol involving nuclear medicine, PET or radiological investigations with significant radiation burden (a significant radiation burden being defined as ICRP category IIb or above: No more than 10 mSv in addition to natural background radiation, in the previous 3 years including the dose from this study).
- •Family history of cancer (one or more first-degree relative diagnosed before the age of 55).
- •History of or suffers from claustrophobia or feels that they will be unable to lie still on their back in the PET camera for a period of 2 hours.
- •History or presence of a neurological diagnosis (not limited to but including for example, stroke, traumatic brain injury, epilepsy, space occupying lesions, multiple sclerosis, Parkinson's disease, vascular dementia, transient ischemic attack, schizophrenia, major depression etc) that may influence the outcome or analysis of the scan results.
- •Presence of a cardiac pacemaker or other electronic device or ferromagnetic metal foreign bodies as assessed by a standard pre-MRI.
结局指标
主要结局
%D3 RO at Tmax
时间窗: approx 1.5 hrs
Percentage occupancy at Tmax
时间窗: approx 1.5 hrs
Ttrough
时间窗: approx 24 hrs
time course of GSK598809 plasma concentration following a single oral dose of GSK598809
时间窗: at predose,1,1.5,2,3,4,8,24 and 48 hrs.
次要结局
- Prolactin/TSH levels(at predose,1, 2, 4,8 & 24 hrs postdose)
- Akathisia(at baseline at 1, 4 hrs postdose)
- EPQ, BIS-BAS:(at screening)
- POMS, CRT:(at predose & 4 hrs postdose)
- VAS:(at predose, 1, 4 hrs postdose)
- LSEQ(at screening, baseline scan & 24 hrs)
- neuroendocrine and behavioural measures following GSK598809 administration.
研究者
研究点 (2)
Loading locations...
相似试验
已完成
1 期
Study Of Safety, Blood Levels, And Brain Receptor Occupancy Of GSK163090 Using PET Imaging In Healthy MalesHealthy SubjectsDepressive Disorder and Anxiety DisordersNCT00435695GlaxoSmithKline13
已完成
1 期
A Positron Emission Tomography (PET) Imaging Study to Investigate the Biodistribution and Clearance of an Albumin Binding Domain Antibody (AlbudAb) GSK3128349 in Healthy Male SubjectsDrug-Related Side Effects and Adverse ReactionsNCT02829307GlaxoSmithKline8
终止
1 期
A Positron Emission Tomography (PET) Study to Investigate the Brain Biodistribution of 18F GSK2647544 in Healthy Subjects to Determine Its Ability to Cross the Blood-brain-barrier.Alzheimer's DiseaseNCT01924858GlaxoSmithKline4
已完成
1 期
A Clinical Study to Investigate the Effect of an Investigational Drug as an Added Medication to an Antipsychotic, in Adults With Schizophrenia, as Measured Positron Emission Tomography (PET) ImagingSchizophreniaNCT04038957Otsuka Pharmaceutical Development & Commercialization, Inc.22
已完成
1 期
PET Study to Determine Muscarinic Receptor Occupancy in Lungs After Inhalation of AZD2115 and TiotropiumHealthy VolunteersNCT03097380AstraZeneca19